| 
            
                             
                             | 
                    
| Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating | 
| Bank Loan Ratings | 5.50 | ACUITE B- | Downgraded | Issuer not co-operating* | - | 
| Total Outstanding | 5.50 | - | - | 
| Total Withdrawn | 0.00 | - | - | 
| * The issuer did not co-operate; based on best available information. | |||
| 
                                    Rating Rationale  | 
                            
| 
                                        
                                             Acuité has downgraded the long-term rating to 'ACUITE B-‘ (read as ACUITE B minus) from ‘ACUITE B’ (read as ACUITE B) on the Rs. 5.50 crore bank facilities of Crescent Formulations Private Limited on account of information risk. The rating continues to be flagged as "Issuer Not-Cooperating" and is based on the best available information.  | 
                                
| About the Company | 
| 
                     Hyderabad based Crescent Formulations Private Limited , a proprietorship concern, was promoted by Mr. Shaik Jainimiya in 1997. Later, the same was converted into a private limited company in 2010. It follows the loan-licensing model for manufacturing of its products. Currently, it is outsourcing from two units - Crescent Therapeutics Limited based out of Solan (Himachal Pradesh) and Suraksha Pharma Private Limited based at Hyderabad. It has nine carryings and forwarding (C&F) agents for marketing and distribution of their products through stockists across Andhra Pradesh, Telangana, Tamil Nadu, Kerala, Karnataka, Maharashtra, and Orissa. All the products are generic drugs only. Presently, it has a product base of about 70 formulations and is waiting for approvals on about 30 products. All the products are prescriptive in nature. They have presence in about 10 therapeutic segments like Neurology, Psychiatry, Ortho, Arthritis, Nutraceutical, Gastro, and General, among others. The drugs are sold under the brand name ‘Crescent’. Its major focus is on Neuro, Psychiatry and Ortho drugs.  | 
            
| Unsupported Rating | 
| Not Applicable | 
| Non-cooperation by the issuer/borrower: | 
| 
                     Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. Acuité believes that information risk is a critical component in such ratings, and non-cooperation by the issuer along with unwillingness to provide information could be a sign of potential deterioration in its overall credit quality. This rating is, therefore, being flagged as “Issuer not-cooperating”, in line with prevailing SEBI regulations and Acuité’s policies.  | 
            
| Limitation regarding information availability | 
| Rating Sensitivity | 
| "No information provided by the issuer / available for Acuite to comment upon." | 
| Liquidity Position | 
| "No information provided by the issuer / available for Acuite to comment upon." | 
| Outlook | 
| Not Applicable | 
| Other Factors affecting Rating | 
| None | 
| Particulars | Unit | FY 24 (Actual) | FY 23 (Actual) | 
| Operating Income | Rs. Cr. | 33.11 | 30.00 | 
| PAT | Rs. Cr. | 1.54 | 1.03 | 
| PAT Margin | (%) | 4.66 | 3.42 | 
| Total Debt/Tangible Net Worth | Times | 0.85 | 1.17 | 
| PBDIT/Interest | Times | 4.39 | 4.91 | 
| Status of non-cooperation with previous CRA | 
| Not Applicable | 
| Any other information | 
| None | 
| Applicable Criteria | 
| 
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm  | 
            
| Note on complexity levels of the rated instrument | 
                                            
  | 
                                    |||||||||||||||||||||||||||||||||||||
|  | 
| 
                                             | 
                                    |||||||||||||||||||||||||||
                                            
  | 
                                    |||||||||||||||||||||||||||
| * The issuer did not co-operate; based on best available information. | |||||||||||||||||||||||||||
Disclosure of list of non-cooperative issuers  | 
| 
• Listed :- https://www.acuite.in/Non-Cooperative_Issuer_Listed.php • Unlisted :- https://www.acuite.in/Non-Cooperative_Issuer_Unlisted.php  | 
            
| 
                                             Contacts  | 
                                    
About Acuité Ratings & Research  | 
                                            
| © Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in | 
